Business Summary
|
Thallion Pharmaceuticals Inc. is a biotechnology company focused on developing new pharmaceutical treatments for oncology and infectious diseases. The Company’s product candidates include Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections, and TLN-4601, a small molecule with potential efficacy in multiple oncology indications. The Company’s Shigamabs product consists of two monoclonal antibodies designed to bind specifically and exclusively to Shigatoxin 1 (Stx1) and Shigatoxin 2 (Stx2) secreted by Shigatoxin-producing E. coli (STEC). The Company has completed four Phase I clinical trials evaluating the safety of Shigamabs, which have demonstrated that the antibodies are safe and well tolerated when administered both individually and in combination at various dose levels. Derived from the Company’s DECIPHER technology, TLN-4601 is a natural product candidate derived from a nonpathogenic microorganism.
| | (Source: ARS)
|
|
|
